ArticleEmerging infectious diseases2023
Successful Treatment of Balamuthia mandrillaris Granulomatous Amebic Encephalitis with Nitroxoline.
Article in Emerging infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Neurosurgical Biopsy and Resection for Diagnosis and Treatment of Balamuthia mandrillaris Amebic Encephalitis, United States.Emerging infectious diseases · 2026Pooled it
- Granulomatous amoebic encephalitis: pathogenesis, diagnostic advances, therapeutic challenges, and emerging treatment strategies.Medical microbiology and immunology · 2026Review
- Investigating the therapeutic potential of the antibacterial drug nitroxoline in combating cryptococcal infection.PLoS neglected tropical diseases · 2026Article
- Fatal Case of Balamuthia Amoebic Encephalitis in a Patient With MOG Antibody-Associated Disease.Open forum infectious diseases · 2026Article
- Disseminated Acanthamoeba Infection with Necrotic Skin Lesions and Granulomatous Vasculitis, United States.Emerging infectious diseases · 2026Article
- Transgenic approaches in the pathogenic free-living amoebae: what are the hurdles?Parasitology · 2026Review
- Drug susceptibility of a clinical isolate ofAntimicrobial agents and chemotherapy · 2026Article
- The first reported case ofFrontiers in medicine · 2026Article
- Imaging findings of Balamuthia mandrillaris amoebic encephalitis in 2 cases with different prognosis and literature review.BMC neurology · 2025Review
- In Vitro Activity of Nitroxoline (5-Nitro-8-Hydroxyquinoline) Against Aspergillus Species.Mycoses · 2025Article
- Next-Generation Sequencing for Diagnosis of Fatal Balamuthia Amoebic Encephalitis: A Case Report.Diagnostics (Basel, Switzerland) · 2025Article
- Repurposing Analysis of Nitroxoline (8-Hydroxy-5-nitroquinoline) as an Antichagasic Compound.Pharmaceuticals (Basel, Switzerland) · 2025Article
- The role of plasma metagenomic sequencing in identification of Balamuthia mandrillaris encephalitis.Acta neuropathologica communications · 2025Article
- Cyclic Peptide Natural Product Inspired Inhibitors of the Free-Living AmoebaJournal of natural products · 2025Article
- Fatal amoebic meningoencephalitis caused byFrontiers in veterinary science · 2025Article
- Brainstorm: A Case of Granulomatous Encephalitis.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2024Article
- Modelling amoebic brain infection caused by Balamuthia mandrillaris using a human cerebral organoid.PLoS neglected tropical diseases · 2024Article
- Primary amebic meningoencephalitis: a review of Naegleria fowleri and analysis of successfully treated cases.Parasitology research · 2024Review
- Drug repurposing for rare: progress and opportunities for the rare disease community.Frontiers in medicine · 2024Article
- Chitosan-based biomaterial delivery strategies for hepatocellular carcinoma.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Funding
Abstract
A patient in California, USA, with rare and usually fatal Balamuthia mandrillaris granulomatous amebic encephalitis survived after receiving treatment with a regimen that included the repurposed drug nitroxoline. Nitroxoline, which is a quinolone typically used to treat urinary tract infections, was identified in a screen for drugs with amebicidal activity against Balamuthia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.